Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
NCT ID: NCT01932385
Last Updated: 2018-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
86 participants
INTERVENTIONAL
2013-08-01
2016-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Residual Plasma Concentration of Sorafenib and Adverse Events in CHC
NCT03340636
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
NCT01033240
Sorafenib PK in Patients With Advanced HCC and Child-Pugh B
NCT04051853
Biomarker Analysis in Sorafenib Treated Hepatocellular Carcinoma Patients
NCT01481805
Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma
NCT02834546
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sorafenib
sorafenib 400mg, oral, twice a day until disease progression defined by RECIST.
Sorafenib
Best Supportive Care
Best Supportive Care
treatment mainly on nutrition and symptoms control
Best Supportive Care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sorafenib
Best Supportive Care
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years to 80 years
* liver function Child-Pugh class B
* BCLC stage B or C
* estimated life time 2 months or longer
Exclusion Criteria
* allergy to Sorafenib
* Uncontrolled Bleeding or diarrhea
* eligible for locoregional treatment
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qingdao Central Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Youxin Ji
Chief, Department of Oncology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ketao lan, M.D.
Role: STUDY_DIRECTOR
Qingdao Health Bereau
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qingdao Central Hospital, Qingdao Cancer Hospital
Qingdao, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QCH20130823
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.